G
GILD
GILDVerified17 segments tracked|6 years of data|Annual (10-K)
Total Revenue
$45.2B4.8%
FY2024
Operating Segments
17Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%HIVProduct Sales
Segment Shift
HIVProduct Sales has grown from 0.0% to 43.4% of total revenue since FY2019, with 0.0% operating margins. Meanwhile, Trodelvy is the fastest growing at +23.7% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| HIVProduct Sales | $19.6B | $0 | 0.0% | 43.4% | +7.9% |
| HIVProducts Biktarvy | $13.4B | $0 | 0.0% | 29.7% | +13.3% |
| HIVProducts Descovy | $2.1B | $0 | 0.0% | 4.7% | +6.4% |
| Veklury | $1.8B | $0 | 0.0% | 4.0% | -17.6% |
| HIVProducts Genvoya | $1.8B | $0 | 0.0% | 3.9% | -14.5% |
| Trodelvy | $1.3B | $0 | 0.0% | 2.9% | +23.7% |
| HIVProducts Odefsey | $1.3B | $0 | 0.0% | 2.8% | -4.6% |
| Liver Disease Products Vemlidy | $959M | $0 | 0.0% | 2.1% | +0.0% |
| HIVProducts Symtuza Revenue Share | $592M | $0 | 0.0% | 1.3% | +0.0% |
| Other Products Am Bisome | $533M | $0 | 0.0% | 1.2% | +0.0% |
| Liver Disease Products Other Liver Disease | $467M | $0 | 0.0% | 1.0% | +0.0% |
| HIVProducts Other HIV | $434M | $0 | 0.0% | 1.0% | +0.0% |
| Cell Therapy Products Tecartus | $403M | $0 | 0.0% | 0.9% | +0.0% |
| Other Products Other | $356M | $0 | 0.0% | 0.8% | +0.0% |
| Royalty Contract And Other | $144M | $0 | 0.0% | 0.3% | -20.9% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free